1. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47–58.
  2. Chen C-J, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
  3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130;678-686.
  4. Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-1319.
  5. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovirdisoproxilfumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
  6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012;57:167–185.
  7. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263–283.
  8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–662.
  9. Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11:285-300.
  10. Viganò M, Mangia G, Lampertico P. Results of treatment of chronic hepatitis B with pegylated interferon. Clin Liver Dis. 2013;17:425-443.
  11. Viganò M, Paggi S, Lampertico P, et al. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. Aliment Pharmacol Ther 2011;34:353-362.
  12. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009;49:1017-1044.
  13. Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-1199.
  14. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-356.
  15. Kim WR, Berg T, Loomba R, et al. Long-term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol 2013;58:S19.
  16. Marcellin P, Gane E, Tsai N, et al. Seven years of treatment with Tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2013;58,4(Suppl 1):649A.
  17. Lampertico P, Soffredini R, Yurdaydin C, et al. Four years of tenofovir monotherapy for NUC naıve field practice European patients suppress HBV replication in most patients with a favourable renal safety profile but do not prevent HCC in patients with or without cirrhosis. Hepatology 2013;58(Suppl 1):653A.
© Effetti srl